Oxford Biomedica Appoints Leone Patterson as Non-Executive Director
April 26 2023 - 7:00AM
Oxford Biomedica Appoints
Leone Patterson as Non-Executive
Director
Oxford, UK –
26th
April
2023: Oxford
Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a
quality and innovation-led viral vector CDMO, today announces the
appointment of Ms Leone Patterson as an Independent Non-Executive
Director. Ms Patterson shall join the Board on 1st May 2023.
Ms Patterson has more than 20 years of public
company biotech experience including in the cell and gene therapy
industry and has managed significant growth within international
commercial companies working across areas including strategy,
finance, operations and governance.
She is currently the Chief Financial and
Business Officer at Tenaya Therapeutics (NASDAQ: TNYA), a
clinical-stage company with a mission to discover, develop, and
deliver potentially curative therapies, including gene therapy, for
heart disease. Ms Patterson also serves on the Board of Directors
for Nkarta (NASDAQ:NKTX), a clinical-stage cell therapy company.
Previously, Ms Patterson held leadership roles, including Chief
Executive Officer and Chief Financial Officer, at Adverum
Biotechnologies, a gene therapy company focused on rare and ocular
diseases. She has also held the role of Chief Financial Officer at
public companies, including diagnostics firm Diadexus and
speciality pharmaceuticals provider Transcept Pharmaceuticals and,
earlier in her career, worked within Novartis, Chiron and KPMG. She
holds a B.S. in business administration and accounting from Chapman
University, an executive M.B.A. from St. Mary's College, and is a
Certified Public Accountant (inactive).
Dr. Roch Doliveux, Chair of Oxford
Biomedica, said: “The appointment of Leone comes at an
important juncture for Oxford Biomedica, as we advance our global
leadership in viral vector development and supply, providing
innovative solutions to our international biopharma customers.
Leone’s deep understanding of corporate finance, her experience of
the US public markets and M&A, in addition to her extensive
experience in the cell and gene therapy industry will be invaluable
in supporting our international strategy and further strengthening
our market position.”
Ms Leone Patterson
said: "I am honoured to be joining the
Board of Oxford Biomedica, a global innovation-led CDMO dedicated
to enabling the development of life-saving cell and gene therapies.
I look forward to working with the Board and contributing my
expertise to help advance the Company's strategy."
Diadexus voluntarily filed for Chapter 7
bankruptcy in June 2016 while Ms. Patterson was its Chief Financial
Officer. Save as disclosed, there are no other disclosures required
to be made in accordance with LR 9.6.13R.
-Ends-
Enquiries:
Oxford Biomedica plc:
Taylor Boyd, VP, Head of IR – T: +1 (984) 268 8488/ E:
ir@oxb.comSophia Bolhassan, VP, Corporate Affairs and IR – T: +44
(0) 7394 562 425 / E: ir@oxb.com
Consilium Strategic Communications: T:
+44 (0)20 3709 5700 / E:
oxfordbiomedica@consilium-comms.com
Mary-Jane Elliott / Matthew Neal / Davide Salvi
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and
innovation-led viral vector CDMO with a mission to enable its
clients to deliver life changing therapies to patients around the
world.
One of the original pioneers in cell and gene
therapy, the Company has more than 25 years of experience in viral
vectors; the driving force behind the majority of gene therapies.
The Company collaborates with some of the world’s most innovative
pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus,
adeno-associated virus (AAV) and adenoviral vectors. Oxford
Biomedica’s world-class capabilities span from early-stage
development to commercialisation. These capabilities are supported
by robust quality-assurance systems, analytical methods and depth
of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is
headquartered in Oxford, UK. It has locations across Oxfordshire,
UK and a US-based subsidiary, Oxford Biomedica Solutions, based
near Boston, MA, US. Learn more at www.oxb.com,
www.oxbsolutions.com, and follow us on LinkedIn, Twitter and
YouTube.
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Nov 2024 to Dec 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Dec 2023 to Dec 2024
